Turning Point Therapeutics, Inc. announced a late-breaker abstract of early clinical data by physician assessment for repotrectinib in NTRK-positive TKI-naïve and TKI-pretreated advanced solid tumor cohorts of TRIDENT-1 has been accepted for oral presentation in a plenary session at the Virtual International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC) on Oct. 7-10. In addition to the late-breaker abstract, two additional abstracts have been selected for presentation at the meeting: Repotrectinib clinical data by physician assessment from the ROS1-positive non-small cell lung cancer TKI-pretreated cohorts (EXP-2, EXP-3 and EXP-4) of TRIDENT-1 and TPX-0022 clinical data by physician assessment from the Phase 1 dose finding portion of SHIELD-1 in patients with advanced solid tumors harboring genetic alterations in MET.